BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2021 1:41:08 AM | Browse: 304 | Download: 528
Publication Name World Journal of Clinical Pediatrics
Manuscript ID 62433
Country/Territory United Kingdom
Received
2021-01-08 12:27
Peer-Review Started
2021-01-08 12:29
To Make the First Decision
Return for Revision
2021-01-25 05:20
Revised
2021-02-12 14:51
Second Decision
2021-05-07 07:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-05-07 11:57
Articles in Press
2021-05-07 11:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2021-05-30 08:37
Publish the Manuscript Online
2021-07-07 01:41
ISSN 2219-2808 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pediatrics
Manuscript Type Evidence Review
Article Title Can omalizumab be used effectively to treat severe conjunctivitis in children with asthma? A case example and review of the literature
Manuscript Source Invited Manuscript
All Author List Stephen Doherty, Melissa Mulholland, Michael Shields and Patrick McCrossan
ORCID
Author(s) ORCID Number
Stephen Doherty http://orcid.org/0000-0001-6396-9984
Melissa Mulholland http://orcid.org/0000-0003-4403-9882
Michael Shields http://orcid.org/0000-0002-3793-3571
Patrick McCrossan http://orcid.org/0000-0001-5242-4866
Funding Agency and Grant Number
Corresponding Author Patrick McCrossan, MBChB, MRCP, Lecturer, Centre of Medical Education, Queens University Belfast, School of Medicine, Dentistry and Biomedical Sciences Whitla Medical Building 97 Lisburn Road , Belfast BT9 7BL, United Kingdom. p.mccrossan@qub.ac.uk
Key Words Omalizumab; Conjunctivitis; Allergy; Asthma; Pediatrics; Atopy
Core Tip Asthma is often associated with multiple atopic conditions which can be more debilitating than the asthma itself. The use of omalizumab has the potential to be effective in the treatment of conjunctivitis associated with asthma and other atopic conditions. However, research is needed to address the question, in the form of multicenter, double-blind randomized control trials.
Publish Date 2021-07-07 01:41
Citation Doherty S, Mulholland M, Shields M, McCrossan P. Can omalizumab be used effectively to treat severe conjunctivitis in children with asthma? A case example and review of the literature. World J Clin Pediatr 2021; 10(4): 48-52
URL https://www.wjgnet.com/2219-2808/full/v10/i4/48.htm
DOI https://dx.doi.org/10.5409/wjcp.v10.i4.48
Full Article (PDF) WJCP-10-48.pdf
Full Article (Word) WJCP-10-48.docx
Manuscript File 62433_Auto_Edited-JPY.docx
Answering Reviewers 62433-Answering reviewers.pdf
Audio Core Tip 62433-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 62433-Conflict-of-interest statement.pdf
Copyright License Agreement 62433-Copyright license agreement.pdf
Peer-review Report 62433-Peer-review(s).pdf
Scientific Misconduct Check 62433-Bing-Fan JR-2.png
Scientific Misconduct Check 62433-Bing-Ma YJ-1.jpg
Scientific Misconduct Check 62433-Scientific misconduct check.pdf
Scientific Editor Work List 62433-Scientific editor work list.pdf